Article info

Download PDFPDF

2SPD-025 Acalabrutinib + obinutuzumab versus ibrutinib + obinutuzumab as first line in chronic lymphocytic leukemia
Free

Authors

Citation

Claramunt García R, Muñoz Cid C, Sánchez Ruiz A, et al
2SPD-025 Acalabrutinib + obinutuzumab versus ibrutinib + obinutuzumab as first line in chronic lymphocytic leukemia

Publication history

  • First published March 23, 2022.
Online issue publication 
April 22, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.